Loading
A phase 2 trial of trastuzumab deruxtecan in lung cancer, run by Memorial Sloan Kettering Cancer Center, now recruiting.
A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer is a phase 2, interventional study registered as NCT07428044 by Memorial Sloan Kettering Cancer Center, with a registry enrolment figure of 14 participants, started 2026-02-13 and due to reach its primary completion in 2027-02-13. Interventions recorded: Trastuzumab Deruxtecan. Conditions listed: Non-Small Cell Lung Cancer; Non-small Cell Lung Cancer Stage II; Non-Small Cell Lung Cancer Stage IIIA; Non-Small Cell Lung Cancer Stage IIIB. Primary outcome: Major Pathologic Response/MPR Rate. Lung eligibility wording from the registry: "* Pathologically documented NSCLC". Sites: Canada, United States. No results are recorded here; the registry entry is the source.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), AstraZeneca and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.